NASDAQ:PYPD PolyPid (PYPD) Stock Price, News & Analysis $6.15 -0.11 (-1.76%) Closing price 04:00 PM EasternExtended Trading$6.18 +0.03 (+0.42%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About PolyPid Stock (NASDAQ:PYPD) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get PolyPid alerts:Sign Up Key Stats Today's Range$6.03▼$6.2550-Day Range$4.72▼$6.6052-Week Range$3.50▼$7.15Volume211,750 shsAverage Volume168,040 shsMarket Capitalization$117.34 millionP/E RatioN/ADividend YieldN/APrice Target$11.67Consensus RatingModerate Buy Company Overview PolyPid Ltd. is an Israeli clinical-stage biopharmaceutical company developing products designed to deliver medicines locally and over an extended period. Its proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology is intended to control the release of drugs at the site where they are administered. The company’s lead product candidate, D-PLEX100, uses the antibiotic doxycycline and is designed to be applied during surgery to provide sustained local drug delivery for the prevention of surgical-site infections. PolyPid has also explored its delivery platform for other medicines and applications. PolyPid is headquartered in Israel and focuses on advancing its drug-delivery technology and product candidates through clinical development. Its products remain investigational and are not established as approved treatments.AI Generated. May Contain Errors. Read More PolyPid Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks64th Percentile Overall ScorePYPD MarketRank™: 3.218307060535 of 5 starsPolyPid scored higher than 64% of companies evaluated by MarketBeat, and ranked 311th out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingModerate Buy Consensus RatingPolyPid has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialPolyPid has a consensus price target of $11.67, representing about 89.7% upside from its current price of $6.15.Amount of Analyst CoveragePolyPid has only been the subject of 3 research reports in the past 90 days.Read more about PolyPid's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for PolyPid are expected to grow in the coming year, from ($0.92) to ($0.61) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of PolyPid is -4.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of PolyPid is -4.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPolyPid has a P/B Ratio of 8.91. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.11% of the float of PolyPid has been sold short.Short Interest Ratio / Days to CoverPolyPid has a short interest ratio ("days to cover") of 3.48, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in PolyPid has recently increased by 98.34%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPolyPid does not currently pay a dividend.Dividend GrowthPolyPid does not have a long track record of dividend growth. News and Social Media3.4 / 5News Sentiment0.47 News SentimentPolyPid has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.59 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 28 news articles for PolyPid this week, compared to 3 articles on an average week.Search Interest3 people have searched for PYPD on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows2 people have added PolyPid to their MarketBeat watchlist in the last 30 days. Company Ownership1.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, PolyPid insiders have not sold or bought any company stock.Percentage Held by Insiders24.70% of the stock of PolyPid is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions26.47% of the stock of PolyPid is held by institutions.Read more about PolyPid's insider trading history. Receive PYPD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PolyPid and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PYPD Stock News HeadlinesHC Wainwright Issues Positive Estimate for PolyPid EarningsNovember 16 at 1:34 AM | americanbankingnews.comFY2029 Earnings Forecast for PolyPid Issued By HC WainwrightNovember 15 at 11:15 AM | americanbankingnews.comDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.November 16 at 1:00 AM | Weiss Ratings (Ad)PolyPid (NASDAQ:PYPD) Earns "Buy" Rating from HC WainwrightNovember 14 at 3:01 AM | americanbankingnews.comPolyPid (NASDAQ:PYPD) Rating Lowered to Hold at Wall Street ZenNovember 14 at 1:31 AM | americanbankingnews.comPolyPid Ltd (PYPD) Q3 2026 Earnings Call Highlights: D-PLEX100 Nears FDA Decision as Azurity ...November 12, 2026 | finance.yahoo.comPolyPid Earnings Call Highlights D-PLEX100 Launch PathNovember 11, 2026 | tipranks.comPolyPid (PYPD) Q3 2026 Earnings Call TranscriptNovember 11, 2026 | fool.comSee More Headlines PYPD Stock Analysis - Frequently Asked Questions How have PYPD shares performed this year? PolyPid's stock was trading at $4.34 at the beginning of 2026. Since then, PYPD shares have increased by 41.7% and is now trading at $6.15. How were PolyPid's earnings last quarter? PolyPid Ltd. (NASDAQ:PYPD) posted its earnings results on Wednesday, November, 11th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.91 by $1.15. The company had revenue of $30 million for the quarter, compared to analyst estimates of $30 million. Read the conference call transcript. When did PolyPid's stock split? PolyPid shares reverse split on Thursday, September 21st 2023.The 1-30 reverse split was announced on Wednesday, September 20th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, September 20th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. When did PolyPid IPO? PolyPid (PYPD) raised $60 million in an initial public offering on Friday, June 26th 2020. The company issued 3,750,000 shares at $15.00-$17.00 per share. Barclays and BMO Capital Markets served as the underwriters for the IPO and Raymond James, National Securities Corporation, Oddo BHF and A.G.P. were co-managers. Who are PolyPid's major shareholders? Top institutional shareholders of PolyPid include AIGH Capital Management LLC (6.53%), Marshall Wace LLP (1.05%), B. Riley Wealth Advisors Inc. (0.11%) and HighTower Advisors LLC (0.07%). How do I buy shares of PolyPid? Shares of PYPD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of PolyPid own? Based on aggregate information from My MarketBeat watchlists, some other companies that PolyPid investors own include Advanced Micro Devices (AMD), Intel (INTC), Walmart (WMT), Energy Transfer (ET), Salesforce (CRM), Johnson & Johnson (JNJ) and Micron Technology (MU). Company Calendar Last Earnings11/11/2026Today11/16/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 PYPD's financial health is in the Green zone, according to TradeSmith. PYPD has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:PYPD CIK1611842 Webwww.polypid.com Phone972-74-719-5700FaxN/AEmployees72Year Founded2008Price Target and Rating Average Price Target for PolyPid$11.67 High Price Target$13.00 Low Price Target$10.00 Potential Upside/Downside+89.7%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($1.35) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$34.17 million Net MarginsN/A Pretax MarginN/A Return on Equity-355.64% Return on Assets-157.69% Debt Debt-to-Equity RatioN/A Current Ratio1.35 Quick Ratio1.35 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.69 per share Price / Book8.91Miscellaneous Outstanding Shares19,083,000Free Float14,369,000Market Cap$117.36 million OptionableOptionable Beta1.43 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:PYPD) was last updated on 11/16/2026 by MarketBeat.com Staff. From Our PartnersA $247 tool for $7Bill Poulos is offering his $247 Instant Scanner for $7 in the Black Friday sale. It's one payment for a full ...Profits Run | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredYour Copy is on Hold (Claim it now)James Altucher, who called NVIDIA in 2008 and SpaceX years before a single share traded, has a new report on E...Paradigm Press | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredSmall-Cap SMX is Taking its Technology into Multiple Trillion-Dollar Industries!SMX (NASDAQ: SMX) uses proprietary molecular-marking technology and a Digital Material Passport platform to gi...Smallcaps Daily | SponsoredThis Tech Could Be Bigger Than Apple, Amazon, and Microsoft CombinedA breakthrough technology backed by Elon Musk, Sam Altman and Jensen Huang could one day be worth more than Ap...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PolyPid Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share PolyPid With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.